



MEDIA RELEASE

VivaZome Therapeutics presents brain injury efficacy data at international exosome conference

1 May 2025, Melbourne, Australia: VivaZome Therapeutics Pty Ltd (“VivaZome”) is delighted to announce that extracellular vesicles (EVs) from its proprietary human cell line have shown promising results in animal models of Traumatic Brain Injury (TBI). These encouraging findings were presented by VivaZome’s Chief Scientific Officer, Professor David Haylock, at the 2025 conference of the International Society of Extracellular Vesicles (ISEV) recently held in Vienna, Austria.

The studies were conducted by our expert collaborators at the Centre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology at University of Queensland (UQ), who have deep expertise in models of brain injury.

The study demonstrated that treatment with VivaZome’s EVs improved motor function, enhanced exploratory behavior and promoted balance 24 hours after moderate TBI. The data also suggests a potential to reduce susceptibility to epileptic seizures. Post-traumatic epilepsy (PTE) is a recurrent seizure disorder that can develop after a TBI. It is a significantly disabling consequence of TBI that affects 1 in 50 people who experience a TBI and can manifest as seizures occurring weeks, months or even years after the initial injury.

Professor David Haylock said: “It is well established that inflammatory mechanisms play a crucial role in the outcomes of TBI. These results provide evidence that the VivaZome’s EVs are dampening the initial inflammatory response, promoting functional recovery. We already know that VivaZome’s EVs contain microRNAs that modulate inflammation and we have demonstrated powerful anti-inflammatory activity in vitro and in other in vivo animal models.”

VivaZome’s CEO and Managing Director, Ms. Xenia Sango said “Traumatic Brain Injury and the associated Post-Traumatic Epilepsy (PTE) are devastating conditions with limited treatment options. Over 700,000 Australians have a brain injury. These results are encouraging as VivaZome pushes on with further preclinical studies and ultimately into clinical trials.”

Emeritus Professor David Reutens, inaugural director of the Centre for Advanced Imaging at UQ and Director of the Royal Brisbane and Women’s Hospital Comprehensive Epilepsy Program commented: “Our collaboration with VivaZome is yielding promising results. Their EVs are showing activity in our models of TBI. Successful translation of these results into the clinical setting has the potential to transform the management of patients with brain injury and with epilepsy”

The VivaZome poster “VivaZome Proprietary Human Cell-Derived Extracellular Vesicles Enhance Recovery After Moderate Traumatic Brain Injury in a Preclinical Model” is available [here](#).

For further information, contact:

Ms Xenia Sango
CEO and Managing Director, VivaZome Therapeutics Pty Ltd
xenia.sango@vivazome.com
+61 (0)406 180 812

About VivaZome:

VivaZome Therapeutics Pty Ltd is a privately-held Australian biotech company, with operational headquarters at the Bio Innovation Hub at La Trobe University in Melbourne, Australia. VivaZome is developing and will commercialise customised EV-based therapies for debilitating and life-threatening disorders, with a focus on neurological conditions, especially Traumatic Brain Injury and associated Post-Traumatic Epilepsy, stroke and dementia.

VivaZome is developing new technologies, intellectual property and manufacturing processes that apply generically to EV therapies. These underpin the Company's development of specific EV products for its target indications. The VivaZome team has extensive expertise in the development and commercialisation of biological therapies, together with a wide network of expert contacts in the Australian and global biotech communities.

VivaZome acknowledges the support of the Department of Industry and Science through the CRC-P program, and the contribution of its CRC-P partners: Australian National University, University of Queensland, La Trobe University, Cytiva and SeerPharma Pty Ltd.

For more information, please visit www.vivazome.com

About the International Society of Extracellular Vesicles (ISEV) Conference:

The 14th ISEV Annual Meeting was held April 23-27, 2025, in Vienna, Austria with the theme of "Universal Communication Breaks Barriers". The meeting covered EV topics from the fundamentals to the newest discoveries in physiology, pathology, and clinical research, including nanotechnology and a broad range of platform technologies, with over 1900 delegates in attendance